Clinical and histological features of the 80 FL cases
| Variables . | No. (%) . | PFS . | P value for PFS . | ||
|---|---|---|---|---|---|
| Median, mo . | 2-year survival, % (95 CI%) . | Univariate analysis . | Multivariate analysis . | ||
| Center | .0396 | .657 | |||
| French | 50 (63) | 62 | 73 (58-84) | ||
| Italian | 30 (37) | 85 | 85 (65-94) | ||
| Age, y | NC | NC | .18 | .179 | |
| Median | 58 | ||||
| Range | 26-83 | ||||
| Hazard ratio | 1.02 | ||||
| Sex | .0742 | .003 | |||
| Male | 39 (49) | 40 | 70 (53-82) | ||
| Female | 41 (51) | 76 | 86 (69-94) | ||
| Histologic grade | .8519 | ||||
| 1 | 42 (53) | 62 | 79 (62-89) | ||
| 2 | 24 (30) | NR | 86 (62-95) | ||
| 3 | 14 (17) | 76 | 63 (33-83) | ||
| Architectural pattern | .9560 | ||||
| Follicular | 71 (90) | 70 | 76 (64-85) | ||
| Follicular and diffuse | 6 (8) | NR | 83 (27-97) | ||
| Diffuse | 3 (2) | 62 | 100 | ||
| Stage | .7422 | ||||
| I | 2 (2) | 19 | 50 (1-91) | ||
| II | 7 (9) | NR | 83 (27-97) | ||
| III | 16 (20) | 76 | 66 (37-84) | ||
| IV | 55 (69) | 70 | 82 (68-90) | ||
| B symptoms | .0982 | .252 | |||
| Present | 28 (35) | 70 | 68 (47-83) | ||
| Absent | 52 (65) | 85 | 83 (69-91) | ||
| BM involvement | .9270 | ||||
| Present | 48 (60) | 70 | 79 (64-89) | ||
| Absent | 32 (40) | 76 | 76 (56-88) | ||
| FLIPI* | .9797 | ||||
| Low risk (0-1) | 15 (19) | 62 | 86 (54-96) | ||
| Intermediate risk (2) | 26 (33) | NR | 79 (57-91) | ||
| High (≥ 3) | 38 (48) | 70 | 74 (55-85) | ||
| GELF | .3138 | ||||
| GELF = 0 | 14 (18) | 62 | 85 (52-96) | ||
| GELF > 0 | 65 (82) | 70 | 76 (62-85) | ||
| Primary treatment | .2685 | .015 | |||
| R-chemotherapy | 68 (85) | 70 | 77 (64-86) | ||
| R-chemotherapy + R | 12 (15) | NR | 82 (45-95) | ||
| Treatment response* | .0015 | .004 | |||
| CR or CRu† | 61 (76) | 70 | 87 (74-93) | ||
| PR‡ | 18 (23) | 28 | 50 (26-70) | ||
| CD8 | .0202 | ||||
| < 10% | 4 (5) | 12 | 50 (6-84) | — | |
| 10%-30% | 39 (49) | 40 | 69 (50-81) | .627 | |
| ≥ 30% | 37 (46) | 85 | 91 (75-97) | .300 | |
| GrzB score | .0008 | < .0001 | |||
| Low | 32 (40) | 40 | 59 (40-74) | ||
| High | 48 (60) | 85 | 93 (79-98) | ||
| Variables . | No. (%) . | PFS . | P value for PFS . | ||
|---|---|---|---|---|---|
| Median, mo . | 2-year survival, % (95 CI%) . | Univariate analysis . | Multivariate analysis . | ||
| Center | .0396 | .657 | |||
| French | 50 (63) | 62 | 73 (58-84) | ||
| Italian | 30 (37) | 85 | 85 (65-94) | ||
| Age, y | NC | NC | .18 | .179 | |
| Median | 58 | ||||
| Range | 26-83 | ||||
| Hazard ratio | 1.02 | ||||
| Sex | .0742 | .003 | |||
| Male | 39 (49) | 40 | 70 (53-82) | ||
| Female | 41 (51) | 76 | 86 (69-94) | ||
| Histologic grade | .8519 | ||||
| 1 | 42 (53) | 62 | 79 (62-89) | ||
| 2 | 24 (30) | NR | 86 (62-95) | ||
| 3 | 14 (17) | 76 | 63 (33-83) | ||
| Architectural pattern | .9560 | ||||
| Follicular | 71 (90) | 70 | 76 (64-85) | ||
| Follicular and diffuse | 6 (8) | NR | 83 (27-97) | ||
| Diffuse | 3 (2) | 62 | 100 | ||
| Stage | .7422 | ||||
| I | 2 (2) | 19 | 50 (1-91) | ||
| II | 7 (9) | NR | 83 (27-97) | ||
| III | 16 (20) | 76 | 66 (37-84) | ||
| IV | 55 (69) | 70 | 82 (68-90) | ||
| B symptoms | .0982 | .252 | |||
| Present | 28 (35) | 70 | 68 (47-83) | ||
| Absent | 52 (65) | 85 | 83 (69-91) | ||
| BM involvement | .9270 | ||||
| Present | 48 (60) | 70 | 79 (64-89) | ||
| Absent | 32 (40) | 76 | 76 (56-88) | ||
| FLIPI* | .9797 | ||||
| Low risk (0-1) | 15 (19) | 62 | 86 (54-96) | ||
| Intermediate risk (2) | 26 (33) | NR | 79 (57-91) | ||
| High (≥ 3) | 38 (48) | 70 | 74 (55-85) | ||
| GELF | .3138 | ||||
| GELF = 0 | 14 (18) | 62 | 85 (52-96) | ||
| GELF > 0 | 65 (82) | 70 | 76 (62-85) | ||
| Primary treatment | .2685 | .015 | |||
| R-chemotherapy | 68 (85) | 70 | 77 (64-86) | ||
| R-chemotherapy + R | 12 (15) | NR | 82 (45-95) | ||
| Treatment response* | .0015 | .004 | |||
| CR or CRu† | 61 (76) | 70 | 87 (74-93) | ||
| PR‡ | 18 (23) | 28 | 50 (26-70) | ||
| CD8 | .0202 | ||||
| < 10% | 4 (5) | 12 | 50 (6-84) | — | |
| 10%-30% | 39 (49) | 40 | 69 (50-81) | .627 | |
| ≥ 30% | 37 (46) | 85 | 91 (75-97) | .300 | |
| GrzB score | .0008 | < .0001 | |||
| Low | 32 (40) | 40 | 59 (40-74) | ||
| High | 48 (60) | 85 | 93 (79-98) | ||
Final cox model contains score, treatment response, primary treatment, and sex.
FL indicates follicular lymphoma; PFS, progression free-survival; CI, confidence interval; NC, not calculated; NR, not reached; FLIPI, Follicular Lymphoma International Prognostic Index; GELF, Groupe d'Etude des Lymphomes Folliculaires; CR, complete response; PR, partial response; CRu, CR unconfirmed; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisone; R-CHOP + R, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone and rituximab maintenance; R-Fludarabine-mitoxantrone + R, rituximab, fludarabine, mitoxantrone, rituximab maintenance; and GrzB, granzyme B.
One patient had no remission after treatment.
Complete response and complete response undefined (according to Cheson criteria [18]).
Partial response.